Application of silent ECM1 gene in resisting PRRSV (porcine reproductive and respiratory syndrome virus) infection

By interfering with ECM1 gene expression and using siRNA to inhibit the invasion and replication of PRRSV, the problem of damage to the lungs by pig reproductive and respiratory syndrome viruses is solved, effective control of PRRSV is achieved, and the development of pig farming industry has been promoted.

CN119185552AActive Publication Date: 2024-12-27AGRI GENOMICS INST CHINESE ACADEMY OF AGRI SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411595573.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-11
Publication Date
2024-12-27
Estimated Expiration
2044-11-11

AI Technical Summary

Technical Problem

Pulmonary damage and chronic lung diseases caused by pig breeding and respiratory syndrome virus (PRRSV) infection are difficult to effectively inhibit virus invasion and replication, affecting the development of the pig farming industry.

Method used

By interfering with ECM1 gene expression, targeting ECM1 transcripts using siRNAs (such as ECM1-sus-668 and ECM1-sus-911) will inhibit the expression of ECM1 protein, thereby affecting the ITGB3-AKT/FAK pathway and reducing the invasion of PRRSV on host cells and copy.

Benefits of technology

It significantly inhibited the replication and invasion of PRRSV in host cells, reduced viral load, provided potential therapeutic targets and pathogenesis research directions, and promoted the development of pig farming industry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119185552A_ABST
    Figure CN119185552A_ABST
Patent Text Reader

Abstract

The invention provides application of a silent ECM1 gene in resisting PRRSV infection, and belongs to the technical field of medicines. The invention provides application of a reagent influencing ECM1 gene expression quantity in preparation of a medicament for regulating and controlling PRRSV (porcine reproductive and respiratory syndrome virus) infected animals and siRNA (small interfering Ribonucleic Acid) for inhibiting the PRRSV infected animals. According to the invention, two kinds of siRNAs are respectively used for interfering with ZMAC-4 cells, and the expression of ECM1 and PRRSV-ORF6 in cells transfected with siRNAs is obviously reduced, which indicates that the interference of the expression of the ECM1 gene has an inhibition effect on the PRRSV infected ZMAC-4 cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to application of silencing ECM1 gene in resisting PRRSV infection. Background Art

[0002] Porcine reproductive and respiratory syndrome is a highly contagious disease of pigs caused by porcine reproductive and respiratory syndrome virus (PRRSV), which can cause reproductive disorders in pregnant sows and respiratory syndrome in weaned piglets, affecting the development of pig farming enterprises. PRRSV infection can be divided into three different stages: acute phase, persistent infection phase and resolution phase. In the acute infection phase, the lungs are the main organs invaded by PRRSV.

[0003] The extracellular matrix (ECM) is a complex network of proteins and proteoglycans, composed of a large number of proteins, including collagen, glycoproteins, and ECM-related proteins, which play a role in supporting, structuring, and regulating cell functions. Remodeling or accumulation of ECM can lead to lung damage and thus cause chronic lung diseases such as pulmonary fibrosis. Therefore, ECM may play a role in PRRSV infection, and the glycoprotein encoded by ECM1 is an important component of ECM. ECM1 protein can interact with other proteins such as collagen and fibronectin to form a structural network that gives tissue strength and elasticity. In addition, ECM1 protein is also associated with disease processes such as tumor development and metastasis, and fibrosis. Therefore, by studying the role of ECM1 in PRRSV infection and exploring the therapeutic targets and pathogenesis of PRRSV infection, it will help promote the development of the pig industry. Summary of the invention

[0004] The present invention provides an application of silencing the ECM1 gene in resisting PRRSV infection, and finds that interfering with the ECM1 expression can inhibit the invasion and replication of PRRSV on host cells.

[0005] The present invention provides the use of a reagent that affects the expression amount of ECM1 gene in the preparation of a medicament for regulating and controlling animals infected with porcine reproductive and respiratory syndrome virus.

[0006] In a specific embodiment of the present invention, the reagent includes a reagent that inhibits the expression of the ECM1 gene.

[0007] In a specific embodiment of the present invention, the agent for inhibiting the expression of ECM1 gene includes siRNA.

[0008] In one embodiment of the present invention, the siRNA includes ECM1-sus-668 and ECM1-sus-911;

[0009] Wherein, ECM1-sus-668 comprises a nucleotide sequence as a sense strand shown in SEQ ID No. 1 and an antisense strand shown in SEQ ID No. 2;

[0010] ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.4.

[0011] The present invention also provides an siRNA for inhibiting porcine reproductive and respiratory syndrome virus infection in animals, wherein the siRNA comprises ECM1-sus-668 and ECM1-sus-911;

[0012] Wherein, ECM1-sus-668 comprises a nucleotide sequence as a sense strand shown in SEQ ID No. 1 and an antisense strand shown in SEQ ID No. 2;

[0013] ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.4.

[0014] In one embodiment of the present invention, the animal comprises a pig.

[0015] The present invention also provides the application of the above siRNA in the study of the mechanism of action of porcine reproductive and respiratory syndrome.

[0016] The present invention also provides the use of the above siRNA in preparing a drug for preventing and / or treating porcine reproductive and respiratory syndrome.

[0017] The present invention also provides application of the siRNA in pig breeding and production.

[0018] Beneficial effects: The present invention provides the use of an agent that affects the expression of the ECM1 gene in the preparation of a medicament for regulating PRRSV infection in animals. In the embodiment, five splice isomers of ECM1 were cloned from normal pig lung tissue, and two siRNAs, namely ECM1-sus-668 and ECM1-sus-911, were used, wherein siRNA (ECM1-sus-668) can target a wider range of transcripts. After siRNA interference with ZMAC-4 cells for 24 hours with siRNA-668 and siRNA-911, PRRSV (XH-GD) was inoculated for 24 hours, and the virus titer was 106.7; the expression of ECM1 and PRRSV-ORF6 in cells transfected with siRNA decreased significantly, indicating that interference with the expression of the ECM1 gene has an inhibitory effect on PRRSV infection of ZMAC-4 cells. And through mechanism research, it was found that ECM1 may affect the invasion and replication of PRSSV on host cells by affecting the ITGB3-AKT / FAK pathway. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a graph showing the relative expression of ECM1 in various tissues;

[0020] Figure 2 is a diagram of coding sequence differences among the five transcripts;

[0021] Figure 3 It is a comparison diagram of the transcript with the corresponding transcript sequence and amino acid sequence in the database;

[0022] Figure 4 The results of si RNA (ECM1-sus-668) and si RNA (ECM1-sus-911) inhibiting the expression of ECM1 and ORF-6 mRNA;

[0023] Figure 5 The figure shows the effect of siRNA (ECM1-sus-911) on the expression of ITGB3, AKT2 and FAK genes. DETAILED DESCRIPTION

[0024] The present invention provides the use of a reagent that affects the expression amount of ECM1 gene in the preparation of a medicament for regulating animals infected with porcine reproductive and respiratory syndrome virus (PRRSV).

[0025] In one embodiment of the present invention, the reagent includes a reagent for inhibiting the expression of the ECM1 gene, and in one embodiment, the expression of the ECM1 gene is interfered with by a siRNA method. In one embodiment of the present invention, when the animal is a pig, the siRNA includes ECM1-sus-668 and ECM1-sus-911; wherein ECM1-sus-668 includes a nucleotide sequence such as a positive strand shown in SEQ ID No.1 and an antisense strand shown in SEQ ID No.2;

[0026] ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.4.

[0027] The ECM1 gene of the present invention includes different transcripts related to the ECM1 gene. In the embodiment, a total of 5 transcripts were verified, and the registration numbers in GenBank (http: / / www.ncbi.nlm.nih.gov / ) are PP885370, PP885371, PP885372, PP885373 and PP885374, respectively. The results of the embodiment show that siRNA (ECM1-sus-668) and siRNA (ECM1-sus-911) are used to inhibit the expression of ECM1 transcripts, wherein siRNA (ECM1-sus-668) can target a wider range of transcripts. The expression of ECM1 in cells transfected with the above two siRNAs is significantly reduced. RT-qPCR was used to detect intracellular RRRSV-ORF6. The results showed that both siRNA (ECM1-sus-668) and siRNA (ECM1-sus-911) interference significantly inhibited PRRSV-ORF6 mRNA expression, indicating that interfering with the expression of the ECM1 gene had an inhibitory effect on PRRSV infection of ZMAC-4 cells.

[0028] ECM1-SUS-668:

[0029] SEQ ID No.1: 5'-GCUGUCACAACUACAUACATT-3';

[0030] SEQ ID No.2: 5'-UGUAUGUAGUUGUGACAGCTT-3';

[0031] ECM1-SUS-911:

[0032] SEQ ID No.3: 5'-CACCCACACUGGACAAUAUTT-3';

[0033] SEQ ID No. 4: 5'-AUAUUGUCCAGUGUGGGUGTT-3'.

[0034] The present invention also provides an siRNA for inhibiting porcine reproductive and respiratory syndrome virus infection in animals, wherein the siRNA comprises ECM1-sus-668 and ECM1-sus-911;

[0035] Wherein, ECM1-sus-668 comprises a nucleotide sequence as a sense strand shown in SEQ ID No. 1 and an antisense strand shown in SEQ ID No. 2;

[0036] ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.4.

[0037] In one embodiment of the present invention, the animal comprises a pig.

[0038] The present invention also provides the application of the above siRNA in the study of the mechanism of action of porcine reproductive and respiratory syndrome.

[0039] The present invention also provides the use of the above siRNA in preparing a drug for preventing and / or treating porcine reproductive and respiratory syndrome.

[0040] The present invention also provides application of the siRNA in pig breeding and production.

[0041] To further illustrate the present invention, the application of the silencing ECM1 gene provided by the present invention in resisting PRRSV infection is described in detail below in conjunction with the examples, but they should not be construed as limiting the protection scope of the present invention.

[0042] Example 1 Expression differences of ECM1 gene in different tissues

[0043] Three 30-day-old Large White pigs (purchased from Zhongshan Baishi Pig Farm) were slaughtered and the heart, liver, spleen, lung, kidney, duodenum, and longissimus dorsi muscle tissue samples were isolated from each pig.

[0044] The total RNA of each tissue sample was extracted by Trizol (Invitrogen), and the RNA concentration was measured by a micro-nucleic acid protein analyzer (Quawell Q500). The integrity of RNA was checked by 1% agarose gel electrophoresis. The reverse transcription first-strand cDNA synthesis kit ( ⅢAll-in-one RT SuperMix PerfectForqPCR), according to the instructions of the kit, 1 μg of total RNA was taken for first-strand cDNA synthesis.

[0045] The expression profile of ECM1 gene in different tissues of pigs was analyzed by fluorescence quantitative PCR. Figure 1 As shown, the ECM1 gene is expressed in the heart, liver, spleen, lung, kidney, large intestine, small intestine, stomach, leg muscle, pancreas, fat and other tissues and organs. GAPDH is used as a housekeeping gene by 2 -ΔΔCt The relative expression of ECM1 in each tissue was calculated. The results showed that the expression of ECM1 mRNA was the highest in adipose tissue, followed by liver tissue. The expression of ECM1 mRNA in leg muscle was relatively the lowest.

[0046] The ECM1 qPCR primer sequences are as follows:

[0047] Q-ECM1-F (SEQ ID No.5): 5'-AGTCCCAGAGGGAGTTTCCA-3';

[0048] Q-ECM1-R (SEQ ID No. 6): 5'-TGCAGCATAGCCAGCTTCTT-3';

[0049] GAPDH qPCR primer sequences are as follows:

[0050] GAPHD-F (SEQ ID No. 7): 5'-GTCGGAGTGAACGGATTTGG-3';

[0051] GAPHD-R (SEQ ID No. 8): 5'-TTGACTGTGCCGTGGAACTT-3'.

[0052] The qPCR reaction system was: 10 μL ChamQ Universal SYBRqPCRMasterMix (Novozymes, Nanjing, China), 0.5 μL upstream primer, 0.5 μL downstream primer, and 1 μL cDNA; the PCR reaction program was: the first step, 95°C for 30 sec; the second step, 95°C for 10 sec, and 60°C for 30 sec; the third step, the instrument default melting curve acquisition program was used.

[0053] Example 2 Cloning of ECM1 transcripts

[0054] Primers were designed to amplify the full-length coding sequence to obtain different alternative splicing variants of ECM1. 1 μL of Large White pig tissue sample cDNA was used as a template for ECM1 gene amplification, and ECM1 gene-specific primers were used.

[0055] ECM1-specific primers are as follows:

[0056] ECM1-F (SEQ ID No. 9): 5'-ATGGGGACCACGTCCAGAGCA-3';

[0057] ECM1-R (SEQ ID No. 10): 5'-TCACTCTTCCTTGGGCTCAAGG-3'.

[0058] The PCR reaction system was: cDNA 1 μL, RNase-free double distilled water 32 μL, upstream primer 2 μL, downstream primer 2 μL, FastPfu Buffer 10μL, and 2.5mM dNTPs 4μL; PCR reaction program: 95℃2min; 95℃20s, 58℃20s, 72℃1min, 35 cycles; 72℃5min.

[0059] Nested PCR ECM1-specific primers are as follows:

[0060] N-ECM1-F (SEQ ID No. 11): 5'-TTCTTGTAGTCCCAGAGGGAGTT-3';

[0061] N-ECM1-R (SEQ ID No. 12): 5'-AGCAGTTGACCTGTTCATCCCC-3'.

[0062] The reaction system of nested PCR was as follows: 1 μL of PCR product, 32 μL of RNase-free double distilled water, 2 μL of upstream primer, 2 μL of downstream primer, FastPfu Buffer 10μL, and 2.5mM dNTPs 4μL; the reaction program of nested PCR was: 95℃2min; 95℃20s, 58℃20s, 72℃1min, 35 cycles; 72℃5min.

[0063] according to 5' / 3' RACE first-strand cDNA synthesis was performed according to the RACE 5' / 3' Kit User Manual (TaKaRa, Dalian, China).

[0064] The reaction procedure is as follows: 42℃90min, 70℃10min. Add 10μL Tricine-EDTA Buffer to dilute the first-strand cDNA and store at -20℃. RACE 5' / 3'Kit User Manual (TaKaRa, Dalian, China) cDNA end rapid amplification program, PCR total reaction system 50μL, 15.5μL PCR-Grade water, 25.0μL 2XSeqAmp Buffer, 1.0μL SeqAmp DNA Polymerase, 5'-or 3'-RACE-Ready cDNA 2.5μL, 10XUPM 5μL and 5'or 3'GSP (10μM) 1μL. PCR reaction conditions 94℃30sec, 68℃30sec, 72℃4min, 30 cycles.

[0065] UPM long (SEQ ID No. 13): 5'-CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT-3';

[0066] GSP3 (SEQ ID No. 14): 5'-ACCCACCGCCACTTGTGTTGCCACCA-3';

[0067] GSP5 (SEQ ID No. 15): 5'-AGGGCTCTGCTGAGAAGTGTCAGGGGGA-3'.

[0068] The PCR products of 5'RACE, 3'RACE and coding region fragments were separated by 1% agarose gel electrophoresis and purified by gel extraction kit (TAKARA, Dalian, China). The purified products and pEASY-Blunt Cloning Vector (TRANS, Beijing, China) vector to fragment molar ratio (1:7) were reacted at room temperature (20℃-37℃) for 5 minutes. The reaction products were transferred into 50μL Trans1-T1 competent cells and flicked to mix, and then placed on ice for 20-30 minutes. Heat shock was performed in a 42℃ water bath for 30 seconds, and then immediately placed on ice for 2 minutes. After adding 250μL SOC medium and shaking culture at 37℃ (200r / min) for 1 hour, the bacterial liquid was evenly coated on LB solid medium containing ampicillin, IPTG and X-gal. After culturing at 37℃ for 14 hours, positive single colonies were selected and cultured in ampicillin liquid medium at 37℃ for 8 hours. Then, the cultured bacterial fluid was detected by PCR, and five alternative splicing variants of ECM1 were detected in pig lung tissue by Sanger sequencing. The five transcripts corresponding to the pig ECM1 annotated in the NCBI database were extracellular matrix protein 1isoform X2 (XM_021089906.1), extracellular matrix protein 1isoform X4 (XM_021089908.1), extracellular matrix protein 1isoform X5 (XM_021089909.1), extracellular matrix protein 1isoform X6 (XM_021089910.1), and extracellular matrix protein 1isoform X7 (XM_021089911.1), which were named ecm1-2, ecm1-4, ecm1-5, ecm1-6, and ecm1-7 according to the corresponding transcript sequences in NCBI. Their sequences have been deposited in GenBank (http: / / www.ncbi.nlm.nih.gov / ) with accession numbers (PP885370), (PP885371), (PP885372), (PP885373), and (PP885374), respectively.

[0069] By comparing the sequences of these five variants, the sequence differences between them were analyzed. Figure 2As shown, the full-length coding sequence of ECM1-2 is 1695bp. Compared with ECM1-2, the full-length coding sequence of ECM1-4 is 1641bp, and 54bp is missing between 391-444bp. The full-length coding sequence of ECM1-5 is 1626bp, and compared with ECM1-2, ECM1-5 has a 69bp deletion between 391-459bp. The full-length coding sequence of ECM1-6 is 1320bp, and compared with ECM1-2, ECM1-6 has a 375bp deletion between 789-1163bp. The full-length coding sequence of ECM1-7 is 1251bp, and compared with ECM1-2, ECM1-7 has a 69bp deletion between 391-459bp and a 375bp deletion between 789-1163bp.

[0070] Example 3 Sequence Analysis of ECM1 Gene

[0071] The open reading frame was predicted using NCBIORF Finder. The protein physicochemical properties were predicted using Expasy software. Signal peptides were predicted using the online prediction software novopro. Transmembrane domains were predicted using the online software TMHMM. The subcellular localization of the target gene was predicted using the online software WoLFPSORT.

[0072] The results are as follows Figure 3 As shown, the five transcripts of the ECM1 gene have only one base difference from the corresponding transcript base sequence in the NCBI database, with a base sequence similarity of 99%, but the encoded proteins are the same. At the same time, they have the same 124bp 5' untranslated region (UTR) and 409bp 3' untranslated region (UTR).

[0073] The software predicted that ECM1s have the same signal peptide type: SP (Sec / SPI); the signal peptide sequence is SEQ ID No. 16 (MGTTSRAALVLAYLAVASVVPEGVS), indicating that ECM1 protein is a secreted protein. WoLF PSORT online software was used to predict that ECM1s subcellular localization is extracellular. And the software predicted that ECM1s does not have a transmembrane domain, further proving that porcine ECM1 protein is a secreted protein.

[0074] Example 4 Silencing of ECM1 differential transcripts inhibits PRRSV infection in ZMAC-4 cells

[0075] Cell culture system: 10% FBS + 1640 medium.

[0076] siRNA (ECM1-sus-668) and siRNA (ECM1-sus-911) were used to inhibit the expression of ECM1 transcripts, among which siRNA (ECM1-sus-668) could target a wider range of transcripts.

[0077] ZMAC-4 cells were seeded on 6-well plates. According to the instructions of the Lipofectamine3000 manufacturer, cells were transfected when they grew to 70% confluence, and Lipofectamine 3000 reagent was diluted with Opti-MEM medium. siRNA was diluted with Opti-MEM medium, mixed thoroughly, and a premix was prepared. The premix (1:1) was added to the diluted Lipofectamine 3000 reagent, diluted for 10-15 minutes, and the mixed solution was added to the cells. 50pM siRNA-668 or siRNA-911 or negative control siRNA-NC were transfected, and siRNA interference was performed for 24 hours, followed by PRRSV (XH-GD) inoculation for 24 hours, and the virus titer was 106.7. The XH-GD strain was donated by Foshan University of Science and Technology and was published in the literature [Cao ZX, Jiao PR, Huang YM, et al. Genetic diversity analysis of the ORF5 gene in porcine reproductive and respiratory syndrome virus samples from South China [J]. Acta Vet Hung, 2012, 60 (1): 157-164.].

[0078] Cell samples were collected, and total cell RNA was extracted and reverse transcribed to synthesize cDNA as described in Example 1. RT-qPCR was performed to analyze the effect of siRNA, wherein NC-PRRSV was the negative control siRNA-NC treatment group; ECM1-sus-668-PRRSV was the siRNA (ECM1-sus-668) treatment group; and ECM1-sus-911-PRRSV was the siRNA (ECM1-sus-911) treatment group. The results are shown in Figure 4 As shown in the figure, the expression of ECM1 in cells transfected with siRNA decreased significantly. RT-qPCR was used to detect intracellular RRRSV-ORF6, and the results showed that both siRNA (ECM1-sus-668) and siRNA (ECM1-sus-911) interference significantly inhibited PRRSV-ORF6 mRNA expression. The results showed that interfering with the expression of the ECM1 gene had an inhibitory effect on PRRSV infection of ZMAC-4 cells.

[0079] The ITGB3-AKT / FAK pathway was detected by RT-qPCR. Figure 5 As shown in the figure, compared with the control group, the expression of ITGB3, AKT2, and FAK mRNA was significantly downregulated in siRNA (ECM1-sus-911) treatment, indicating that ECM1 may affect the invasion and replication of PRSSV in host cells by affecting the ITGB3-AKT / FAK pathway.

[0080] The siRNA (ECM1-sus-668) sequence is as follows:

[0081] SEQ ID No.1: 5'-GCUGUCACAACUACAUACATT-3';

[0082] SEQ ID No.2: 5'-UGUAUGUAGUUGUGACAGCTT-3';

[0083] The siRNA (ECM1-sus-911) sequence is as follows:

[0084] SEQ ID No.3: 5'-CACCCACACUGGACAAUAUTT-3';

[0085] SEQ ID No.4: 5'-AUAUUGUCCAGUGUGGGUGTT-3';

[0086] The siRNA (NC) sequence is as follows:

[0087] SEQ ID No.25: 5'-UUCUCCGAACGUGUCACGUTT-3';

[0088] SEQ ID No. 26: 5'-ACGUGACACGUUCGGAGAATT-3'.

[0089] PRRSV-ORF6 qPCR primer sequences are as follows:

[0090] PRRSV-ORF6-F (SEQ ID No. 17): 5'-TTTGACTGGGCAGTGGAGAC-3';

[0091] PRRSV-ORF6-R (SEQ ID No. 18): 5'-AGGAAATGGCTGGTGGTGAG-3';

[0092] ITGB3 qPCR primer sequences are as follows:

[0093] ITGB3-F (SEQ ID No. 19): 5'-GAGTTCCCCATCAGTGAGGC-3';

[0094] ITGB3-R (SEQ ID No. 20): 5'-CTCTTCGAATCATCTGGCCG-3';

[0095] The AKT2 qPCR primer sequences are as follows:

[0096] AKT2-F (SEQ ID No. 21): 5'-GGGTTCTCCAGAACACCAGG-3';

[0097] AKT2-R (SEQ ID No. 22): 5'-CAGGTGGAAAAACAGCTCGC-3';

[0098] The FAK qPCR primer sequences are as follows:

[0099] FAK-F (SEQ ID No. 23): 5'-TGCTGGACCTCTGAACTAATATGAC-3';

[0100] FAK-R (SEQ ID No. 24): 5'-GTGCCCAGGTGAGTCTTGG-3'.

[0101] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Application of reagents that affect the expression of ECM1 gene in the preparation of medicaments for regulating animals infected with porcine reproductive and respiratory syndrome virus.

2. The application according to claim 1, characterized in that: The reagents include reagents for inhibiting the expression of ECM1 gene.

3. The application according to claim 2, characterized in that: The reagent for inhibiting the expression of ECM1 gene includes siRNA.

4. The use according to claim 3, characterized in that: The siRNAs include ECM1-sus-668 and ECM1-sus-911; Wherein, ECM1-sus-668 comprises a nucleotide sequence as a sense strand shown in SEQ ID No. 1 and an antisense strand shown in SEQ ID No. 2; ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.

4.

5. An siRNA for inhibiting porcine reproductive and respiratory syndrome virus infection in animals, characterized in that: The siRNAs include ECM1-sus-668 and ECM1-sus-911; Wherein, ECM1-sus-668 comprises a nucleotide sequence as a sense strand shown in SEQ ID No. 1 and an antisense strand shown in SEQ ID No. 2; ECM1-sus-911 includes a sense strand as shown in SEQ ID No.3 and an antisense strand as shown in SEQ ID No.

4.

6. The siRNA according to claim 5, characterized in that The animals include pigs.

7. Use of the siRNA according to claim 5 or 6 in the study of the mechanism of action of porcine reproductive and respiratory syndrome.

8. Use of the siRNA according to claim 5 or 6 in the preparation of a drug for preventing and / or treating porcine reproductive and respiratory syndrome.

9. Use of the siRNA according to claim 5 or 6 in pig breeding and production.

Citation Information

Patent Citations

  • Application of extracellular matrix protein 1 and regulator thereof in preparing medicament for diagnosing or treating allergic diseases

    CN102552910A

  • Application of ECM1 molecular marker in preparing bladder cancer detection reagent and reagent

    CN109486953A

  • SiRNA recombinant plasmid based on PRRSV genome dsRNA as well as construction method and application of siRNA recombinant plasmid

    CN118165990A

  • Improved host cells for AAV vector production

    WO2024075012A1